Vertex Pharmaceuticals (VRTX) EBT (2009 - 2026)

Vertex Pharmaceuticals' EBT history runs 18 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• On a quarterly basis, EBT rose 71.54% year-over-year to $1.3 billion in Q1 2026; TTM through Mar 2026 was $5.2 billion, a 1820.75% increase from a year earlier, with the FY2025 full-year figure at $4.6 billion, up 1768.49% from the prior year.
• EBT fell to $1.3 billion in Q1 2026 per VRTX's latest filing, from $1.3 billion in the prior quarter.
• Across five years, EBT topped out at $1.3 billion in Q4 2025 and bottomed at -$3.4 billion in Q2 2024.
• The 5-year median for EBT is $1.2 billion (2023), against an average of $868.0 million.
• Across the five-year window, EBT jumped 2417.65% in 2022 and slumped 391.97% in 2024, its largest moves.
• Year by year, EBT stood at $1.1 billion in 2022, then grew by 6.58% to $1.1 billion in 2023, then slipped by 0.97% to $1.1 billion in 2024, then gained by 17.11% to $1.3 billion in 2025, then declined by 5.87% to $1.3 billion in 2026.
• Per Business Quant, the three latest VRTX EBT figures stand at $1.3 billion (Q1 2026), $1.3 billion (Q4 2025), and $1.3 billion (Q3 2025).